GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
P

Preveceutical Medical PREV.CN · CAD

N/A · Canadian Securities Exchange · 🇨🇦 Canada

Compare

0.02

0.00%

Close of 9 Nov 2026, in CAD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Popular Bitcoin Ethereum Nvidia Apple S&P 500 Gold EUR/USD US 10Y

At a glance

Figures in CAD, from our data supplier.

FY2022

Revenue

—

FY2016FY2022

Net income

−C$1.5m

FY2016FY2022

Free cash flow

−C$222,600

FY2016FY2022

Shareholders' equity

−C$4.6m

FY2016FY2022

Income statement

Fiscal years

FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue———C$3,000C$15,500C$22,200C$31,100
Research and developmentC$78,400C$62,200C$212,600C$1.7mC$2.4mC$517,600—
Operating income−C$1.1m−C$897,900−C$2.1m−C$3.5m−C$6.9m−C$4.5m−C$2.7m
Net income−C$1.5m−C$1.7m−C$3.8m−C$3.6m−C$11.9m−C$7.2m−C$3.1m
Diluted earnings per share-0.00-0.00-0.01-0.01-0.04-0.16-0.07

Balance sheet

At each fiscal year end

FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assetsC$189,100C$161,200C$302,500C$857,600C$1.9mC$2.6mC$207,200
Cash and short-term investmentsC$5,600C$16,100C$156,400C$28,500C$64,300C$104,500—
Total liabilitiesC$4.8mC$4.3mC$3.9mC$5.3mC$4.2mC$2.9mC$503,200
DebtC$3.3mC$2.9mC$3.0mC$4.7mC$3.7mC$2.7mC$131,600
Shareholders' equity−C$4.6m−C$4.1m−C$3.6m−C$4.5m−C$2.3m−C$344,300−C$296,100
Shares outstanding522m508m456m396m319m45m45m

Cash flow

Fiscal years

FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations−C$222,600−C$426,400C$64,600−C$993,900−C$7.6m−C$4.3m−C$1.3m
Capital spending—−C$55,200−C$2,700−C$1,300−C$10,600−C$193,000−C$403,200
Free cash flow−C$222,600−C$481,600C$61,900−C$995,200−C$7.6m−C$4.5m−C$1.7m

Latest quarters

By quarter end

Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024Jun 2024Mar 2024Dec 2023
Operating income−C$771,800−C$1.2m−C$674,700−C$153,300−C$241,500−C$275,500−C$142,100−C$352,700
Net income−C$817,800−C$1.2m−C$763,600−C$241,600−C$335,800−C$362,000−C$235,400−C$423,100
Diluted earnings per share-0.00-0.00-0.00-0.00-0.00-0.00-0.00-0.00
Total assetsC$456,000C$361,700C$259,200C$225,700C$454,700C$177,400C$186,200C$181,500
Cash and short-term investmentsC$103,700C$4,300C$5,500C$59,100C$200C$200C$2,800C$1,400
DebtC$708,400C$738,300C$860,100C$796,700C$710,400C$684,100C$595,600C$470,900
Shareholders' equity−C$7.4m−C$7.2m−C$7.2m−C$6.6m−C$6.3m−C$6.3m−C$6.0m−C$5.8m

Growth per year

Compound annual rate

3 years5 years10 years
Operating income-32.9%-25.1%—
Net income-25.5%-27.2%—

Valuation history

At each fiscal year end

FY2022FY2021FY2020FY2019FY2018FY2017
Price to earnings-5.3-4.4-2.2-1.0-0.8-0.3
Price to sales—————113.7

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 1-to-1 reverse split · 25 Nov 2025
  • 5-for-1 split · 23 May 2018
  • 3-to-1 reverse split · 14 Jul 2017

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.